Eli Lilly 'Sabotaged' Rezpeg's Development, Nektar Tells Jury
Eli Lilly & Co. breached its deal with Nektar Therapeutics to co-develop the autoimmune-disease drug Rezpeg and instead "sabotaged" its development in favor of a different Eli Lilly drug, a Nektar...To view the full article, register now.
Already a subscriber? Click here to view full article